• 1
    Armitage, JM, Kormos, RL, Stuart, RS (1991) Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 10:877886.
  • 2
    Barkholt, L, Billing, H, Juliusson, G, Porwit, A, Ericzon, B, Groth, C (1991) B-cell lymphoma in transplanted liver: clinical, histological and radiological manifestations. Transpl Int 4:811.
  • 3
    Cook, RC, Connors, JM, Gascoyne, RD, Fradet, G, Levy, RD (1999) Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 354:16981699.
  • 4
    Davis, CL, Wood, BL, Sabath, DE, Joseph, JS, Stehman-Breen, C, Broudy, VC (1998) Interferon-α treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66:17701779.
  • 5
    Faye, A, van den Abeele, T, Peuchmaur, M, Mathieu-Boue, A, Vilmer, E (1998) Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 352:12851290.
  • 6
    Fischer, A, Blanche, S, Le Bidot, J, Bordigoni, P, Griscelli, C, Hirn, M (1991) Anti-B-cell antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:14511456.
  • 7
    Grillo-López, AJ, White, CA, Dallaire, BK (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol [Suppl 14] 26:6673.
  • 8
    Harris, NL, Swerdlow, SH, Frizzera, G, Knowles, DM (2001) Post-transplant lymphoproliferative disorders. In: Jaffe, ES, Harris, NL, Stein, H, Vardiman, JW (eds) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC Press, Lyon, pp 264269.
  • 9
    Leblond, V, Sutton, L, Dorent, R, Davi, F, Bitker, M-O, Raphael, M (1995) Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single centre. J Clin Oncol 13:961968.
  • 10
    Lien, Y-H, Schroter, GPJ, Weil, III R (1991) Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant patient with acute pancreatitis. Transplantation 52:739742.
  • 11
    Milpied, N, Vasseur, B, Parquet, N, Faye, A, Leblond, V (2000) Humanized anti-CD20 monoclonal antibody (rituximab) in posttransplant lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 [suppl 1]:113116.
  • 12
    Nalesnik, M, Makowka, L, Starzl, TE (1988) The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 25:367372.
  • 13
    Niedobitek, G, Mutimer, DJ, Williams, A, Whitehead, L, Wilson, P, Rooney, N, Young, LS, Hübscher, SG (1997) Epstein-Barr virus infection and malignant lymphomas in liver transplant recipients. Int J Cancer 73:514520.
  • 14
    Oertl, SH, Anagnostopoulos, I, Bechstein, WO, Liehr, H, Riess, HB (2000). Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation Transplantation 69:430432.
  • 15
    Paya, CV, Fung, JJ, Nalesnik, MA, Kieff, E, Green, M, Bromberg, JS (1999) Epstein-Barr-virus-induced posttransplant lymphoproliferative disorders. Transplantation 68:15171525.
  • 16
    Penn, I (1990) Cancer complicating organ transplantation. N Engl J Med 323:17671769.
  • 17
    Raymond, E, Tricottet, V, Samuel, D, Reynes, M, Bismuth, H, Misset, JL (1995) Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer 76:13441351.
  • 18
    Reff, ME, Carner, K, Chambers, KS (1994) Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 83:435445.
  • 19
    Spiro, IJ, Yandell, DW, Chuan Li, SD, Saini, S, Ferry, J, Cosimi, AB (1993) Lymphoma of donor origin occurring in the porta hepatis of a transplanted liver. N Engl J Med 329:2729.
  • 20
    Starzl, TE, Porter, KA, Iwatsuki, S (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1:583587.
  • 21
    Steiber, AO, Boillot, O, Starzl, TE (1991) The surgical implications of the posttransplant lymphoproliferative disorders. Transplant Proc 23:14771479.
  • 22
    Swinnen, LJ (1999) Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 26 [suppl 14]:2125.
  • 23
    Swinnen, LJ, Costanzo-Nordin, MR, Fisher, SG, O'Sullivan, EJ, Fisher, RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323:17231728.
  • 24
    Swinnen, LJ, Mullen, GM, Carr, TJ, Costanzo, MR, Fisher, RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:33333340.
  • 25
    Zompi, S, Tulliez, M, Conti, F, Leblond, V, Gaulard, P, Bouscary, D (2000) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 32:521527.